Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
In Re: BRCA1- and BRCA2- Based Hereditary Cancer Test Patent Litigation
Case Number:
2:14-md-02510
Court:
Nature of Suit:
Multi Party Litigation:
Multi-district Litigation
Judge:
Firms
- Dentons
- Fish & Richardson
- Foley & Lardner
- Groombridge Wu
- Hatch Law Group
- Jones Waldo
- Kilpatrick Townsend
- Kirkland & Ellis
- Magleby Cataxinos
- McDermott Will & Emery
- Morrison Foerster
- Parr Brown
- Parsons Behle
- Paul Weiss
- Pillsbury Winthrop
- Ray Quinney
- Robins Kaplan
- Sterne Kessler
- Thorpe North
- TraskBritt
Companies
- AARP Inc.
- Ambry Genetics Corp.
- American Civil Liberties Union
- Counsyl Inc.
- Invitae Corp.
- Myriad Genetics Inc.
- Pathway Genomics Corp.
- Quest Diagnostics Inc.
Sectors & Industries:
-
February 06, 2015
Myriad Settles With Quest In Cancer Gene Test Patent MDL
Myriad Genetics Inc. on Friday settled patent infringement litigation with Quest Diagnostics Inc., dismissing claims in Utah federal court alleging Quest infringed Myriad's patents for BRCA cancer gene testing, some of which had been recently invalidated by the Federal Circuit.
-
January 26, 2015
Myriad Settles Cancer Test Patent Suits With 3 Defendants
Three of the seven companies that Myriad Genetics Inc. has accused of infringing its patents on breast cancer tests — Pathway Genomics Corp., Invitae Corp. and Laboratory Corporation of America Holdings — reached settlements with the molecular diagnostic company on Friday.
-
March 11, 2014
Myriad Loses Bid To Block Ambry Cancer Tests In Patent Row
A Utah federal judge on Monday halted Myriad Genetics Inc.'s quest to block sales of Ambry Genetics Corp. cancer-testing products it claims infringe several of its patents, including five tackled in a landmark U.S. Supreme Court decision last year, ruling that Ambry had raised sufficient questions about the patents' validity.